Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $108.8 million.

  • Pulse Biosciences' Liabilities and Shareholders Equity rose 1689.38% to $108.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.9 million, marking a year-over-year increase of 10466.31%. This contributed to the annual value of $132.5 million for FY2024, which is 12392.4% up from last year.
  • Latest data reveals that Pulse Biosciences reported Liabilities and Shareholders Equity of $108.8 million as of Q3 2025, which was up 1689.38% from $120.3 million recorded in Q2 2025.
  • Over the past 5 years, Pulse Biosciences' Liabilities and Shareholders Equity peaked at $133.4 million during Q1 2025, and registered a low of $39.5 million during Q1 2022.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $74.8 million (2023), whereas its average is $77.9 million.
  • Per our database at Business Quant, Pulse Biosciences' Liabilities and Shareholders Equity plummeted by 5092.42% in 2022 and then skyrocketed by 19744.48% in 2025.
  • Quarter analysis of 5 years shows Pulse Biosciences' Liabilities and Shareholders Equity stood at $59.2 million in 2021, then surged by 31.65% to $77.9 million in 2022, then dropped by 24.04% to $59.2 million in 2023, then soared by 123.92% to $132.5 million in 2024, then decreased by 17.89% to $108.8 million in 2025.
  • Its last three reported values are $108.8 million in Q3 2025, $120.3 million for Q2 2025, and $133.4 million during Q1 2025.